{"id":67442,"date":"2026-06-05T14:10:14","date_gmt":"2026-06-05T06:10:14","guid":{"rendered":"https:\/\/flcube.com\/?p=67442"},"modified":"2026-06-05T14:10:15","modified_gmt":"2026-06-05T06:10:15","slug":"mabwell-bioscience-secures-nmpa-clinical-approval-for-9mw5211-in-inflammatory-bowel-disease-highly-specific-depleting-antibody-targets-pathogenic-immune-cells","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67442","title":{"rendered":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>9MW5211<\/strong> in <strong>inflammatory bowel disease (IBD)<\/strong>, an indication that previously received U.S. regulatory clearance for clinical trials.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Inflammatory bowel disease (IBD)<\/td><\/tr><tr><td><strong>Additional Indications Under Review<\/strong><\/td><td>Multiple sclerosis (MS) and other autoimmune diseases<\/td><\/tr><tr><td><strong>U.S. Status<\/strong><\/td><td>Previously approved for clinical trials<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Highly specific depleting novel antibody<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> 9MW5211 \u2013 <strong>highly specific depleting novel antibody<\/strong><\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> Binds to molecule specifically expressed on surface of <strong>pathogenic immune cells<\/strong><\/li>\n\n\n\n<li><strong>Pathological Basis:<\/strong> Abnormal activation and tissue infiltration of immune cells drive onset and progression of autoimmune diseases<\/li>\n\n\n\n<li><strong>Biomarker Significance:<\/strong> Target serves as <strong>important biomarker for abnormal immune cell activation<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> <strong>Selectively recognizes and depletes pathogenic cells<\/strong>, effectively blocking immune cascade reaction<\/li>\n\n\n\n<li><strong>Therapeutic Outcome:<\/strong> Alleviates disease progression and improves clinical symptoms<\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> <strong>Excellent target selectivity<\/strong> with significantly reduced risk of non-specific binding<\/li>\n\n\n\n<li><strong>Efficacy Profile:<\/strong> Achieves <strong>deep depletion of pathogenic cells<\/strong> with high target protein expression while maintaining safety<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Status<\/th><th>Market Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>Inflammatory Bowel Disease (IBD)<\/strong><\/td><td>NMPA clinical approval secured<br>Previously approved in US<\/td><td>Global IBD market valued at $25+ billion<br>China represents 15-20% of global patient population<br>High unmet need for targeted therapies<\/td><\/tr><tr><td><strong>Multiple Sclerosis (MS)<\/strong><\/td><td>Under clinical review in China<\/td><td>MS affects ~100,000 patients in China<br>Limited treatment options with significant side effects<br>Premium pricing for effective disease-modifying therapies<\/td><\/tr><tr><td><strong>Other Autoimmune Diseases<\/strong><\/td><td>Potential expansion indications<\/td><td>Broad applicability across autoimmune spectrum<br>Platform validation for multiple high-value indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Current Autoimmune Therapies<\/th><th>9MW5211 Advantages<\/th><\/tr><\/thead><tbody><tr><td><strong>Broad Immunosuppressants<\/strong><\/td><td>Non-specific immune suppression<br>Increased infection risk<br>Variable efficacy<\/td><\/tr><tr><td><strong>Existing Biologics<\/strong><\/td><td>Target cytokines or general immune pathways<br>Primary\/secondary non-response common<\/td><\/tr><tr><td><strong>Development Risk<\/strong><\/td><td>High attrition rates in autoimmune drug development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-mabwell\" class=\"wp-block-heading\">Strategic Implications for Mabwell<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands beyond oncology into high-value autoimmune therapeutic area<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Parallel regulatory progress in US and China accelerates worldwide development timeline<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates Mabwell&#8217;s antibody discovery and engineering capabilities<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Leverages existing biologics commercial expertise in Chinese market<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong clinical data could attract international partnership interest for ex-China rights<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approvals, clinical development, and commercial expectations for 9MW5211. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402722_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060402722_c.\"><\/object><a id=\"wp-block-file--media-27d6a3ce-977c-43a1-a79b-8f1d85598432\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402722_c.pdf\">2026060402722_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402722_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-27d6a3ce-977c-43a1-a79b-8f1d85598432\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,118,1129],"class_list":["post-67442","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67442\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67442\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T06:10:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T06:10:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells\",\"datePublished\":\"2026-06-05T06:10:14+00:00\",\"dateModified\":\"2026-06-05T06:10:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67442#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67442\",\"name\":\"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T06:10:14+00:00\",\"dateModified\":\"2026-06-05T06:10:15+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67442\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67442#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67442","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.","og_url":"https:\/\/flcube.com\/?p=67442","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T06:10:14+00:00","article_modified_time":"2026-06-05T06:10:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67442#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67442"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells","datePublished":"2026-06-05T06:10:14+00:00","dateModified":"2026-06-05T06:10:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67442"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67442#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67442","url":"https:\/\/flcube.com\/?p=67442","name":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T06:10:14+00:00","dateModified":"2026-06-05T06:10:15+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for 9MW5211 in inflammatory bowel disease (IBD), an indication that previously received U.S. regulatory clearance for clinical trials.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67442#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67442"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67442#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease \u2013 Highly Specific Depleting Antibody Targets Pathogenic Immune Cells"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67442"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67442\/revisions"}],"predecessor-version":[{"id":67445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67442\/revisions\/67445"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}